September 2016 edition

Our September edition is available to read now. The issue features companies and insight articles focused on next-generation antibodies, platform biotech technologies and the rapidly moving area of immuno-oncology.

Like Comment

Read the newly released September edition of BioPharma Dealmakers.

Browse through the companies working in the antibodies, regenerative medicine and immuno-oncology fields and looking for partnerships -


Aspyrian Therapeutics

BeyondSpring Pharmaceuticals

Crescendo Biologics




GroK Technologies


MAB Discovery

MS Ventures

Oslo Cancer Cluster


Precision Biosciences


This issue also features our three in-depth articles that chart the checkpoint inhibitors in the rapidly growing immuno-oncology field, follow the progress of bi-specific antibodies and highlights the new-found independence of platform biotechs.

Charting checkpoint inhibitors

Bispecific antibody platforms spawn dealmaking boom

Platform biotechs bring out pharma’s creative side

Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research

Hello all, I am the Editor of BioPharma Dealmakers, a quarterly publication that assists companies in identifying potential partners in the pharmaceutical and biotechnology industry and appears in both Nature Biotechnology and Nature Reviews Drug Discovery. I am very passionate about the biopharma industry and have over 15 years of experience of working in the field, specifically in dealmaking, partnering and licensing. In my previous roles I have conducted partner searches identifying both products/technologies and partners for clients, and have edited and written dealmaking-focused reports.

No comments yet.